Scars After Central Venous Catheters
- Conditions
- Hypertrophic ScarsKeloids
- Interventions
- Drug: Betamethason-17-valerate and fusidic acid
- Registration Number
- NCT01113125
- Lead Sponsor
- Mette Møller Handrup
- Brief Summary
Most children with cancer need a central venous catheter. These catheters are typically placed on the anterior thorax, where the risk of hypertrophic scarring and keloid development is greatly enhanced. A significant part of the children who have survived childhood cancer are troubled by their scars.
Topical glucocorticoid treatment is known to induce a reduction of the collagen in the connective tissue.
The investigators hypothesize that treatment with topical glucocorticoids for one week before and three weeks after removal of a central venous catheter, will reduce the formation of hypertrophic scarring and keloid development in children.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- All children and adolescents who have a central venous catheter removed at the Childrens Department of Oncology at Aarhus University Hospital Skejby in the period from March 2010 to July 2011
- Known allergy towards plaster or fusidic acid
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fucicort Betamethason-17-valerate and fusidic acid - Fucidin Fusidic Acid -
- Primary Outcome Measures
Name Time Method scars measured by the Vancouver Scar Scale twelve months after central venous catheter removal Twelve months
- Secondary Outcome Measures
Name Time Method Judgement of the scar by Patient and observer scar scale after six months six months Judgement of the scar by Patient and observer scar scale after twelve months twelve months scars measured by the Vancouver Scar Scale six months after central venous catheter removal six months
Trial Locations
- Locations (1)
Arhus University Hospital Skejby
🇩🇰Aarhus, Aarhus N, Denmark